Abstract
The aim was to observe the effects of switching from neutral protamine Hagedorn (NPH) insulin to insulin glargine on glycaemic control in patients with type 2 diabetes mellitus (T2DM) in everyday clinical practice in Italy. This multicenter, observational, retrospective study included 1,011 patients with T2DM who switched from NPH insulin to glargine or were maintained on NPH insulin. The primary outcome was change in HbA1c over 4–8 months. Secondary outcomes included fasting blood glucose (FBG), insulin dose, and hypoglycaemia. The intention-to-treat population consisted of 996 patients (glargine 496; NPH 500). Prior to switching, HbA1c was higher in the glargine than the NPH group [mean (±SD) 8.8 ± 1.4 vs. 7.9 ± 1.2 %; p < 0.001]. HbA1c decreased after 4–8 months with glargine (8.2 ± 1.4 %; p < 0.001) but not with NPH (8.0 ± 1.4 %; p = 0.20). Similar results were observed for FBG. The daily dose of glargine increased from 0.22 ± 0.10 U/kg at the switch to 0.26 ± 0.11 U/kg at study end, while the NPH dose remained stable (0.19 ± 0.09–0.20 ± 0.09 U/kg). While not statistically significant, the percentage of patients with hypoglycaemic episodes during the last month of treatment tended to be less with glargine. No significant change in body weight occurred in either group. Switching patients from NPH insulin to insulin glargine in a real-life setting was associated with significant improvement in glycaemic control. The increase in glargine dose was not accompanied by increased hypoglycaemia or weight gain.
Similar content being viewed by others
References
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787
Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiniansen JS (2003) Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 20:63–71
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649
Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di VA, Cordoni C, Costa E, Brunetti P, Bolli GB (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148
Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086
Yki-Jarvinen H, Dressler A, Ziemen M (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23:1130–1136
Massi BM, Humburg E, Dressler A, Ziemen M (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35:189–196
Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636
American Diabetes Association (2013) Standards of medical care in diabetes—2013. Diabetes Care 36(Suppl 1):S11–S66
Associazione Medici Diabetologi—Societa Italiana di Diabetologia - Diabete Italia. Standard Italiani per la Cura del Diabete Mellito. Linee-Guida e Raccomandazioni. Edizioni Infomedica. http://www.siditalia.it/linee-guida/. Accessed 16 October 2012
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH (2013) American Association of Clinical Endocrinologists comprehensive diabetes management algorithm 2013. Endocr Pract 19:327–336
Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S (2005) The gap between guidelines and reality: type 2 diabetes in a national diabetes register 1996–2003. Diabet Med 22:1420–1426
Schreiber SA, Haak T (2007) Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 9:31–38
Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P (2009) Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol 8:9
Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM (2007) Comparison of insulin glargine versus NPH insulin in people with type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 115:349–353
Delgado E (2012) Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. Int J Clin Pract 66:281–288
Shestakova M, Glinkina I (2009) Insulin glargine (GLAR) and NPH insulin (NPH) in real life in Russia in patients with Type 2 diabetes (T2D) (abstract). Diabetes 58(Suppl 1):2060-PO
Cimino A, de Bigontina G, Fava D, Giorda C, Meloncelli I, Nicolucci A, Pellegrini F, Rossi MC, Vespasiani G (2008) Quality indicators in diabetes care in Italy. AMD annals. Associazione Medici Diabetologi, Torino
Davies M, Sinnassamy P, Storms F, Gomis R (2008) Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract 79:368–375
Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD (2010) A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 64:1609–1618
Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P (2009) Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 8:3
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282–1288
Calvert MJ, McManus RJ, Freemantle N (2007) Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 57:455–460
Goodall G, Sarpong EM, Hayes C, Valentine WJ (2009) The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 9:19
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al.; Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al.; ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379
Acknowledgments
The study was supported by a research grant from Sanofi, Paris, France. The funding source (Sanofi) participated in initial discussions about trial design and performed the data analysis and preparation of study reports. The authors had access to all data, participated in the analysis and interpretation of data. The authors vouch for the completeness and veracity of the data and analyses.
Conflict of interest
The authors have no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Massimo Federici.
The study is conducted on behalf of the Italian LAUREL Study Group which is given in the online appendix.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bellia, A., Babini, A.C., Marchetto, P.E. et al. Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. Acta Diabetol 51, 269–275 (2014). https://doi.org/10.1007/s00592-013-0531-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-013-0531-5